Breast cancer outcome prediction with tumour tissue images and machine learning by Turkki, R et al.
Vol.:(0123456789) 
Breast Cancer Research and Treatment (2019) 177:41–52 
https://doi.org/10.1007/s10549-019-05281-1
PRECLINICAL STUDY
Breast cancer outcome prediction with tumour tissue images 
and machine learning
Riku Turkki1,11  · Dmitrii Byckhov1 · Mikael Lundin1 · Jorma Isola2 · Stig Nordling3 · Panu E. Kovanen4 · 
Clare Verrill5,6 · Karl von Smitten7 · Heikki Joensuu8 · Johan Lundin1,9 · Nina Linder1,10
Received: 10 December 2018 / Accepted: 16 May 2019 / Published online: 22 May 2019 
© The Author(s) 2019
Abstract
Purpose Recent advances in machine learning have enabled better understanding of large and complex visual data. Here, 
we aim to investigate patient outcome prediction with a machine learning method using only an image of tumour sample 
as an input.
Methods Utilising tissue microarray (TMA) samples obtained from the primary tumour of patients (N = 1299) within a 
nationwide breast cancer series with long-term-follow-up, we train and validate a machine learning method for patient 
outcome prediction. The prediction is performed by classifying samples into low or high digital risk score (DRS) groups. 
The outcome classifier is trained using sample images of 868 patients and evaluated and compared with human expert clas-
sification in a test set of 431 patients.
Results In univariate survival analysis, the DRS classification resulted in a hazard ratio of 2.10 (95% CI 1.33–3.32, p = 0.001) 
for breast cancer-specific survival. The DRS classification remained as an independent predictor of breast cancer-specific 
survival in a multivariate Cox model with a hazard ratio of 2.04 (95% CI 1.20–3.44, p = 0.007). The accuracy (C-index) 
of the DRS grouping was 0.60 (95% CI 0.55–0.65), as compared to 0.58 (95% CI 0.53–0.63) for human expert predictions 
based on the same TMA samples.
Conclusions Our findings demonstrate the feasibility of learning prognostic signals in tumour tissue images without domain 
knowledge. Although further validation is needed, our study suggests that machine learning algorithms can extract prognos-
tically relevant information from tumour histology complementing the currently used prognostic factors in breast cancer.
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DSS  Disease-specific survival
DRS  Digital risk score
ECW  Enhanced wavelet compression
ER  Oestrogen receptor
GMM  Gaussian mixture model
HER2  Human epidermal growth factor receptor 2
HR  Hazard ratio
IFV  Improved Fisher vector
OS  Overall survival
PCA  Principal component analysis
PR  Progesterone receptor
SVM  Support vector machine
TIL  Tumour-infiltrating lymphocytes
TMA  Tissue microarray
Background
There is a growing interest around the potential of machine 
learning to improve the accuracy of medical diagnostics [1]. 
Novel machine learning techniques have not only advanced 
the state-of-the-art in several pattern recognition tasks [2, 3], 
but also have the potential to extract clinically relevant infor-
mation from complex medical imaging data sets. Especially, 
methods using deep learning have been successful in various 
medical image analysis tasks [4, 5], some of them reaching 
performance of experienced specialists in individual diag-
nostic tasks [6, 7].
Within pathology, whole-slide scanners have enabled 
accurate digitisation of histological samples with sub-micro-
metre resolution allowing for computerised analysis of the 
specimens with machine learning algorithms [8]. Comput-
erised methods for detection of mitoses [9–11], infiltrating 
immune cells [12, 13] and other tissue entities such as seg-
mentation of epithelial and stromal tissue compartments or 
discrimination between viable and non-viable tissue [14–18] 
have been studied. Recent reviews [5, 8, 19] offer thorough 
summaries on methods developed for analysis of histologi-
cal samples.
Specific type of deep learning methods, convolutional 
neural networks (CNNs), is frequently used in the develop-
ment of the image-based classifiers. CNNs are composed 
of consecutive, interconnected and hierarchical stages—an 
architecture inspired by the structure of biological neural 
networks [20]—making it a powerful tool to capture abstract 
patterns in visual data. Utility of CNNs was recently dem-
onstrated in detection of breast cancer metastases in lymph 
node tissue sections [21].
Instead of predicting patient outcome based on inter-
mediate quantification of tissue structures, such as spe-
cific cell types and states (e.g. mitotic cells, pleomorphic 
cells, immune cells) or tissue structures and entities (ducts, 
necrosis, vessels), our aim in this study is to predict patient 
outcome based solely on the visual appearance of the breast 
cancer tissue without any prior assumptions. We hypoth-
esise that a method capable of inferring relevant signals for 
outcome without prior knowledge of tissue structures may 
be able to reveal complementary and unbiased prognostic 
information.
Materials and methods
Patients and preparation of tumour tissue 
microarrays
We pooled two data sets for the study, the FinProg series and 
a similar single-centre series from Helsinki University Cen-
tral Hospital. The FinProg series (N = 1860) is a nationwide 
cohort including approximately 50% of all women diagnosed 
with breast cancer in Finland 1991 and 1992 [22] and cover 
most of the patients (93%) within five selected geographi-
cal regions (the FinProg Breast Cancer Database1). The 
other patient series (N = 527) consists of patients diagnosed 
mainly in the Helsinki region and treated at the Department 
of Surgery and Oncology, Helsinki University Hospital, 
from 1987 to 1990. Both series include comprehensive infor-
mation on clinical and pathologic characteristics extracted 
from the hospital and laboratory records. In the current 
study, we used information on histological grade and type, 
tumour size, number of positive lymph nodes, patient age, 
as well as oestrogen (ER), progesterone (PR) and human 
epidermal growth factor receptor 2 (HER2) status. In addi-
tion, we had information on treatment type given; 62% of 
the patient received local therapy and 42% systemic therapy.
Routinely fixed paraffin-embedded breast cancer samples 
were retrieved from the archives of pathology laboratories, 
and representative tumour regions identified for prepara-
tion of TMA blocks [23]. From the tissue blocks available, 
three representative 0.60 mm tissue cores were punched and 
assembled into 23 TMA blocks, each containing 50–144 
tumour tissue cores. Immunohistochemistry, chromogen 
in situ hybridisation, as well as grading [24] were performed 
as previously described [22].
Inclusion criteria for the current study were the follow-
ing: survival data with cause of death, images of the breast 
tumour tissue, as well as a tissue sample area > 0.02 mm2 
(corresponding to 400,000 pixels in the image). Patients 
with lobular or ductal carcinoma in situ, synchronous or 
metachronous bilateral breast cancer or other malignancy 
(except for basal cell carcinoma or cervical carcinoma 
in situ), distant metastasis, or who did not undergo surgery 
of the primary tumour were excluded. In addition, the TMAs 
1 http://www.finpr og.org.
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that were checked for quality and non-representative, sam-
ples without tumour tissue, were excluded. After exclusions, 
1299 tissue spots, one per patient, were available for further 
analysis. Lastly, the spots were randomly divided into sepa-
rate training (N = 868, 67%) and test (N = 431, 33%) sets. 
Compared to the commonly used 80–20% split, we assigned 
more samples (33%) to the test set in order to also enable 
subgroup and multivariate analyses. The median follow-up 
of patients in the final patient cohort alive at the end of fol-
low-up period is 15.9 years (range 15.0–20.9, interquartile 
range 15.4–16.3 years).
Image acquisition
Five-micrometre thick sections were cut from the TMA 
blocks, stained with haematoxylin and eosin and digit-
ised with a whole-slide scanner (Pannoramic 250 FLASH, 
3DHISTECH Ltd., Budapest, Hungary) equipped with a 
20 × objective (numerical aperture 0.80) and a 1 × adapter, 
and a progressive scan colour camera with three separate 
charge-coupled devices with 1 618 × 1 236 pixels sized 
4.40 μm × 4.40 μm (CIS_VCC_F52U25CL, CIS Corpora-
tion, Tokyo, Japan) resulting in an image where one pixel 
represents an area of 0.22 μm × 0.22 μm. Images were stored 
in a whole-slide image format (MRX, 3DHISTECH Ltd., 
Budapest, Hungary) and further compressed to a wavelet file 
format (Enhanced Compressed Wavelet, ECW, ER Mapper, 
Intergraph, Atlanta, GA) with a compression ratio of 1:10. 
The compressed virtual slides were uploaded to a whole-
slide image management server (WebMicroscope, Aifo-
ria Technologies Oy, Helsinki, Finland) where individual 
images of TMA spots were segmented from the whole-slide 
image and downloaded for algorithm training and testing as 
uncompressed portable network graphics files.
Outcome classification
We extracted local convolutional image descriptors for 
each TMA spot image by reading the activations from the 
last convolutional layer of convolutional neural network 
(VGG-16) trained on the ImageNet database [25], and used 
improved Fisher vector (IFV) encoding [26] to aggregate 
the descriptors from the image foreground regions into a 
single descriptor. The network used (VGG-16) is a 16-layer 
network with small 3 × 3 convolutional filters. The network 
was not trained or fine-tuned on our data set, instead we 
used it only as a feature extractor. A benefit of the descrip-
tor aggregation approach is that an image of arbitrary size 
can be given as an input for the model. In addition, a study 
[27] showed that descriptor aggregation with IFV might 
yield stronger discrimination when compared to fully con-
nected layers. For computation of the IFV, the convolu-
tional image descriptors were compressed with principal 
component analysis (PCA) from 512 channels into 16 com-
ponents, and 64 mixture components were used in quantis-
ing the data with a Gaussian mixture model (GMM). We 
defined the image foreground regions by applying Otsu’s 





+ 2e)∕2e , and where Ig is a Gaussian-fil-
tered (radius of 15 pixels) grayscale version (averaged over 
colour channels) of the spot image. After the thresholding, 
all objects smaller than 12,500 pixels in area were removed. 
Finally, we compressed the IFV descriptors with PCA into 
48 bins before classification with a linear support vector 
machine (SVM). The analysis pipeline was implemented in 
a numerical computing environment (MATLAB R2016b, 
MathWorks, Natick, MA, U.S.) using libraries for computer 
vision and machine learning [29–31].
For training the DRS group classifier, we defined two 
categories according to the patients’ survival status and 
follow-up time. In the first category (high risk, N = 340), 
we included all the patients who died due to breast cancer 
earlier than 10 years after the diagnosis, and in the other 
category (low risk, N = 528), we included the patients who 
did not die of breast cancer during the entire follow-up time. 
For learning the unsupervised IFV encoding, we randomly 
sub-sampled 4 × 106 local image descriptors from the train-
ing set. The sampling was balanced between low-risk and 
high-risk spots. In training the SVM model, we used 868 
breast cancer TMA spot images, each spot representing an 
individual patient.
Visual risk scoring
Three pathologists scored the test set TMA spot images into 
low and high-risk groups using a web-based viewing and 
annotation software (WebMicroscope, Aiforia Technologies 
Oy, Helsinki, Finland). Prior and during the visual scor-
ing, the pathologists were able to view the training set TMA 
spots grouped as they were labelled in training of the SVM 
classifier. Based on the pathologists’ scoring, a visual risk 
score (high risk or low risk) was formed with majority vot-
ing. Furthermore, one pathologist assessed the following 
tissue entities in each TMA spot: mitoses (0 vs. 1 vs. > 1), 
pleomorphism (minimal vs. moderate vs. marked), tubules 
(≤ 10 vs. 10–75 vs. > 75%), necrosis (absent vs. present) and 
quantity of tumour-infiltrating lymphocytes (TILs) (low vs. 
high).
Statistical analysis
The Kaplan–Meier method was used for estimating the sur-
vival function [32] and the log-rank test was used in compar-
ison of survival curves. The disease-specific survival (DSS) 
time was defined as the time period between date of diagno-
sis and death of breast cancer, censoring patients who were 
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alive on the date of the last contact, and those who had died 
from another cause on the date of death. The overall survival 
(OS) time was defined as the time period between the date 
of breast cancer diagnosis and death of any cause, censoring 
patients alive on the date of the last contact. For estimating 
the effect size (hazard ratio, HR) while accounting for the 
effect of other covariates, we used the Cox proportional haz-
ard model [33]. C-index (concordance) and AUC were used 
to evaluate the discrimination and prediction accuracy of 
survival models [34]. Chi-squared contingency table test was 
used for comparison of categorical variables, and continuous 
distributions were compared with Kruskal–Wallis test. All 




We trained the outcome classifier using a training set of 868 
tumour tissue images, and subsequently classified the test 
set representing 431 breast cancer patients into low and high 
DRS groups (Fig. 1). In the test set, 237 (55%) patients were 
classified into the low DRS group and 194 (45%) patients 
into the high DRS group. The patient characteristics are 
summarised in Table 1. The DRS model performance rates 
measured with area under receiver operating characteristics 
curve (AUC) on the test and training sets were 0.58 and 
0.63, respectively, indicating no substantial model overfit-
ting (Supplementary Fig. S1).
Outcome classification and clinicopathological 
variables
Patients predicted to have an increased risk of breast cancer-
specific death had significantly greater proportion of high-
grade tumours (p = 0.014) as compared to patients who were 
assigned to the low DRS group (Table 1). Moreover, patients 
in the high DRS group had larger tumours (p < 0.001), higher 
number of positive lymph nodes (p = 0.003) and were more 
often PR-negative (p = 0.015).
Outcome classification and survival analysis
We investigated the prognostic value of the DRS grouping 
with univariable and multivariable survival analysis in the 
test set. Women in the lower DRS group had more favour-
able breast cancer-specific (p < 0.001) and overall survival 
(p = 0.003) (Fig. 2). Ten-year DSS in the low DRS group was 
82% (95% CI 77–87%) compared to 65% (95% CI 58–73%) 
in the high DRS group. When the cancers were split accord-
ing to histological grade assessed from original whole-slide 
samples, the DRS grouping showed the strongest discrimina-
tion in grade I cancer (P < 0.001), whereas the differences 
observed in grade II (p = 0.410) and grade III (p = 0.083) 
groups were not statistically significant (Fig. 3). When the 
cancers were divided according the steroid hormone recep-
tor status, the DRS classifier was a significant predictor of 
survival both in the ER positive (p = 0.025) and ER negative 
(p < 0.001) subgroups. The DRS grouping was a significant 
predictor in the PR-negative subgroups, but not in the sub-
set of PR-positive breast cancer (p = 0.003). Furthermore, 
 








Low risk    High risk 
Model parameters are 
learned from the training 
data only. 
Survival analysis of the risk 




Feature extraction  
with a deep CNN 
Feature pooling with  
IFV and PCA  
High risk 
Low risk 
Risk group  
classification  
with SVM 
The computational pipeline. 
Fig. 1  Workflow for training and testing the digital risk score (DRS) 
classification. The computational pipeline consists of three sequential 
steps: (i) feature extraction with a deep convolutional neural network 
(CNN), (ii) feature pooling with improved Fisher vector encoding 
(IFV) and principal component analysis (PCA) and (iii) classification 
with support vector machine (SVM). Training set samples are used in 
supervision and a separate test set-up used in validation
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the risk grouping was a significant predictor for survival 
both among HER2 negative (p = 0.015) and positive patients 
(p < 0.001). Subgroup analysis according to tumour size and 
nodal status are shown in Figure 4.
A multivariate survival analysis showed that classification 
into the high DRS group was associated with unfavourable 
prognosis (HR = 2.04, 95% CI 1.20–3.44, p = 0.007), and 
indicated that the DRS grouping is an independent predictor 
for survival (Table 2). Tumour size (1.04, 95% CI 1.02–1.06, 
p < 0.001), PR positivity (0.42, 95% CI 0.25–0.71, p < 0.001) 
and having > 10 positive lymph nodes (HR = 4.74, 95% CI 
1.17–19.30, p < 0.029) were also independent predictors.
Table 1  Patient characteristics
Left association of clinicopathological variables in the training and test sets. Right: association of clinico-
pathological variables between patients in low and high digital risk score (DRS) groups
p-values < 0.05 are shown in bold










% N % N % N % N
Number of positive lymph nodes
 Mean 1.4 1.2 0.407 0.9 1.6 0.003
 0 58 504 59 253 0.323 63 150 53 103 0.057
 1–3 24 206 23 99 23 54 23 45
 4–9 8 73 9 38 6 15 12 23
  > 10 3 30 2 7 1 2 3 5
 Unknown 6 55 8 34 7 16 9 18
Tumour size (per mm)
 Mean 23.7 23.2 0.817 2.15 25.3 < 0.001
 Unknown 3 28 5 22 5 13 5 9
Histological grade
 I 16 143 19 83 0.086 23 54 22 43 0.014
 II 34 296 36 154 32 75 41 79
 III 23 197 18 76 14 33 22 43
 Unknown 27 232 27 118 32 75 22 43
Histological type
 Ductal 76 662 77 333 0.742 74 175 81 158 0.079
 Lobular/special 24 206 23 98 26 62 19 36
Age
  ≤ 39 7 63 7 30 0.353 9 21 5 9 0.140
 40–49 21 186 24 103 27 64 20 39
 50–59 27 234 22 94 21 49 23 45
 60–69 20 172 21 91 20 47 23 44
  ≥ 70 25 213 26 113 24 56 29 57
ER
 Negative 29 248 27 116 0.572 25 60 29 56 0.443
 Positive 62 538 64 274 65 155 61 119
 Unknown 9 82 10 41 9 22 10 19
PR
 Negative 42 362 41 177 0.803 36 86 47 91 0.015
 Positive 49 423 50 215 56 132 43 83
 Unknown 10 83 9 39 8 19 10 20
HER2
 Negative 72 623 74 321 0.713 76 181 72 140 0.136
 Positive 17 146 16 70 14 32 20 38
 Unknown 11 99 9 40 10 24 8 16
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Outcome classification and visual risk score
Out of the 431 test TMA spot images, 109 were classified 
by at least one pathologist as not evaluable due to insuf-
ficient amount of cancer tissue or partial spot detachment 
for reliable risk assessment and were therefore left out from 
the analyses.
In the remaining subset of 322 spot images, 60% 
(N = 193) of the patients were assigned to the low-risk and 
40% (N = 129) to the high-risk group according the major-
ity vote visual risk score, as compared to 55% (N = 177) 
low risk and 45% (N = 145) high risk according to the DRS 
groups. Percent agreement between the pathologists’ indi-
vidual scorings was 32%. There was a significant agreement 
between pathologist 1 and 3 (κ(1,3) = 0.27; p < 0.001), but 
not between pathologist 1 and 2 (κ(1,2) = 0.005; p = 0.931) or 
pathologist 2 and 3 (κ(2,3) = − 0.028; p = 0.598) in assigning 
the patients into low- and high-risk groups.
In a univariate analysis, the digital risk score was found 
to be a significant predictor of disease-specific survival with 
a HR = 2.10 (95% CI 1.40–3.18, p < 0.001) and C-index of 
0.60 (95% CI 0.55–0.65). Similarly, the visual risk score 
was found to be a significant predictor of survival with a 
HR = 1.74 (95% CI 1.16–2.61, p = 0.006) and C-index of 
0.58 (95% CI 0.53–0.63) (Supplementary Fig. 2). Interest-
ingly, a Chi-square test of these univariate survival mod-
els indicated that the models were significantly differ-
ent (p < 0.001). When the visual risk score and the DRS 
group were both included as covariables in a multivariate 
survival analysis, both turned out to be independent pre-
dictors (HR = 2.05, p < 0.001 for the DRS and HR = 1.68, 
p = 0.012 for the visual risk score). C-index of the combined 
survival model was 0.64 (95% CI 0.58–0.69). An analysis of 
the association between cancer morphological features and 
the digital risk score showed that the DRS was significantly 
correlated with nuclear pleomorphism and tissue tubule for-
mation, whereas the visual risk score was significantly asso-
ciated also with cancer mitotic count, presence of necrosis 
and the number of TILs (Supplementary Table 1).
Discussion
We found that by utilising machine learning algorithms it 
is possible to extract information relevant for breast cancer 
patient outcomes from tumour tissue images stained for the 
basic morphology only. Importantly, the results show that 
prognostic discrimination is achievable without guidance 
or the use of prior knowledge of breast cancer biology or 
pathology in the training of the algorithm. Instead of direct-
ing the focus towards cancer cellular features (e.g. number 
of mitotic cells, immune cells, pleomorphic cells) or tissue 
entities (e.g. duct formation, presence of tumour necrosis), 
we guided the supervision simply with the patient survival 
outcome data.
Computerised methods for analysing breast tissue images 
for patient prognostication have been studied earlier. Extract-
ing more than 6000 predefined image features from two 
Fig. 2  Disease-specific survival (DSS) and overall survival (OS) according the classification into low and high digital risk score (DRS) groups
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Fig. 3  Disease-specific survival (DSS) according the classification into low and high digital risk score (DRS) groups
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cohorts (N = 248 and N = 328), authors in [35] showed that 
it is feasible to learn an outcome predictor for overall sur-
vival (HR = 1.78, p = 0.017) using small tumour regions. 
Using a subset of the whole slides from [36], an earlier study 
[37] proposed a joint analysis of image features and gene 
expression signatures for prognostic biomarker discovery. 
The authors used a training set of 131 patients and validated 
the biomarkers with H&E-stained tumour samples from 65 
breast cancer patients. The strongest predictive image feature 
the authors identified reached a HR = 1.7 (p = 0.002) in pre-
diction of relapse-free survival. Moreover, a previous work 
[38] identified morphological features in a data set of 230 
breast cancer patients that were independent and prognostic 
for 8-year disease-free survival. Our study extends this body 
of work by demonstrating that it is possible to learn a prog-
nostic signal from a patient cohort without domain knowl-
edge. Our analysis was blinded from the fundamental con-
cepts such as cells and nuclei, different tissue compartments 
and histological grade that were incorporated in the previous 
studies. Nevertheless, we were able to train an independent 
risk predictor based on the training cohort, using the raw 
image data and follow-up information only. Furthermore, we 
Fig. 4  Disease-specific survival (DSS) according the classification into low and high digital risk group (DRS) groups in patients with different 
tumour size and nodal status
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used a large multicentre cohort with a median follow-up time 
of over 15 years and analysed the associations of the out-
come predictor with the commonly used clinicopathological 
variables. Outside breast cancer, direct outcome prediction 
using tissue morphology has been successfully applied in 
colorectal cancer [39] and glioma [40].
Moreover, we compared the DRS group with the visual 
risk score, which combined three pathologists’ risk assess-
ments according to a majority vote rule. Even though 
Table 2  Cox uni- and 
multivariate survival analysis
Histological grade and type were assessed from whole tumour sections, while ER, PR and HER2 were 
assessed from TMAs. In order to meet the Cox proportionality assumption, ER was left out from the multi-
variate analysis and grade II and III were combined
ER estrogen receptor status, PR progesterone receptor status, HER2 human epidermal growth factor recep-
tor 2 gene amplification
p-values < 0.05 are shown in bold
Variables Univariate analysis Multivariate analysis
HR CI 95% p value HR CI 95% p Value
DRS
 Low Ref. Ref.
 High 2.10 (1.33–3.32) 0.001 2.04 (1.20–3.44) 0.007
Number of positive 
lymph nodes
 0 Ref. Ref.
 1–3 1.53 (0.89—2.63) 0.123 2.12 (0.83–1.47) 0.116
 4–9 2.93 (1.61–5.33) < 0.001 2.15 (0.75–6.19) 0.154
  > 10 7.43 (2.90–19.02) < 0.001 4.75 (1.17–19.30) 0.029
Tumour size
 Per mm 1.04 (1.03–1.06) <0.001 1.04 (1.02–1.06) <0.001
Histological grade
 I Ref. Ref.
 II or III 3.14 (1.61–6.09) < 0.001 1.57 (0.76–3.20) 0.220
Histological type
 Ductal Ref Ref.
 Lobular/special 0.73 (0.40–1.33) 0.306 0.90 (0.41–1.95) 0.782
Age
 ≤ 39 Ref. Ref.
 40–49 0.78 (0.33–1.88) 0.585 0.43 (0.17–1.12) 0.084
 50–59 0.69 (0.28–1.70) 0.425 0.48 (0.19–1.28) 0.144
 60–69 1.00 (0.42–2.36) 0.996 0.62 (0.25–1.57) 0.319
  ≥ 70 1.58 (0.66–3.79) 0.306 1.35 (0.49–3.72) 0.564
ER
 Negative Ref.
 Positive 0.69 (0.44–1.09) 0.15
PR
 Negative Ref. Ref.
 Positive 0.34 (0.21–0.55) < 0.001 0.42 (0.25–0.71) 0.001
HER2
 Negative Ref.
 Positive 1.51 (0.90–2.53) 0.119 1.07 (0.57–1.98) 0.831
Systematic therapy
 Not given Ref. Ref.
 Given 1.90 (1.21–2.98) 0.005 1.07 (0.22–1.47) 0.245
Local therapy
 Not given Ref. Ref
 Given 1.23 (0.75–2.03) 0.404 1.22 (0.61–2.46) 0.571
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pathologists do not perform such a direct risk assessment 
as part of breast cancer diagnostics, we wanted to evaluate 
the prognostic potential of morphological features detected 
by pathologists in a small tumour tissue area (a TMA core) 
and compare this with the corresponding digital risk score. 
The analysis indicated that the visual risk score was a sig-
nificant predictor of outcome, but that the digital risk score 
yielded a slightly stronger discrimination than the visual 
risk score (C-index 0.60 vs. 0.58). As expected, the visual 
risk score correlated with known tissue entities (mitoses, 
pleomorphism, tubules, necrosis and TILs). Interestingly, the 
DRS group associated only with pleomorphism and tubules, 
indicating that the machine learning algorithm partly has 
learned known prognostic entities, but partly has extracted 
features that are not fully explained by known factors. This 
was supported by multivariate survival analysis with DRS 
and visual risk score, which showed increased discrimina-
tion (C-index 0.64), and revealed that the risk scores are 
independent prognostic factors.
One of the main reasons behind the success of deep learn-
ing and CNNs has been improved availability of large data 
sets [41, 42]. The best-performing CNNs for object detec-
tion and classification are trained with millions of images 
[43–45]. Contrary to classification based on handcrafted 
image descriptors and shallow learners, CNN inherently 
learns hierarchical image features from data, and larger data 
set usually leads into more powerful models. This ability to 
learn features directly from the data makes CNNs perform 
well and why they are easy to use. However, when only lim-
ited number of data points is available, direct end-to-end 
training of a CNN might not lead into any added benefit over 
handcrafted features and a shallow classifier.
Our goal in the design of the computational pipeline 
for patient outcome classification was to combine the best 
from the both worlds; the descriptive power of CNNs with 
the capability of shallow learners to generate robust mod-
els from more limited data set. Generally, this approach is 
known as transfer learning, which is a popular strategy to 
achieve a strong performance even with smaller data sets 
[46, 47]. We took advantage of a CNN trained on the Ima-
geNet [48], a large database for object recognition, and 
used it for extracting local image descriptors. An important 
benefit of this approach is less computational requirements, 
since training of the CNN is not needed. Furthermore, the 
approach is agnostic with regard to the CNN used and is 
easily amendable and compatible with novel model archi-
tectures frequently discovered and shared online for the 
research community. The ImageNet consists of photographs 
representing natural objects from bicycles to goldfish.2 His-
tological images are fundamentally different from everyday 
photos and it is reasonable to assume that the descriptors 
learned in natural images are not optimally suited for analy-
sis of tumour tissue images. IFV is an orderless descriptor 
aggregation method, capturing the first- and second-order 
statistics of the GMM modes. The GMM modes were 
learned in the training set of tumour tissue images, and 
therefore this intermediate unsupervised learning phase 
further fine-tunes the features more suitable to the domain 
of histological images.
Our study has some important limitations. The cohort 
used in this study was centrally scanned using the same slide 
scanner and therefore the generalisation of the outcome pre-
diction to tissue images from other slide scanners was not 
taken into consideration. Moreover, our study considered 
only small tumour area in the form of a TMA spot image.
Although our analysis indicated correlation with the com-
puterised prediction and pleomorphism and tubules, a major 
limitation of the current work is the difficulty to explain the 
exact source and location of the predictive signal, i.e. which 
tissue regions gave rise to the result obtained. Deep learning 
models are considered as “black boxes”, which work well, 
but whose function, or reasoning, is difficult to reveal [49]. 
Some approaches to answer this shortcoming have been pre-
sented [50], but this is an active research question in field 
of machine learning and no direct solution for this exists at 
present. We intend to address this in the future studies.
Our findings indicate that computerised methods offer 
an innovative approach for analysing histological samples. 
Nevertheless, future studies are required to validate our find-
ings, test similar algorithms on larger data sets representing 
different malignancies.
Conclusions
We have demonstrated how machine learning analysis of 
tumour tissue images can be utilised for breast cancer patient 
prognostication. Our results show that it is possible to learn a 
risk grouping, providing independent prognostic value com-
plementing the conventional clinicopathological variables, 
using only digitised tumour tissue images and patient out-
come as the endpoint. These findings suggest that machine 
learning algorithms together with large-scale tumour tis-
sue image series may help approximate the full prognostic 
potential of tumour morphology.
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